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Abstract. 
 
During the process of lymphocyte recircula-
tion, lymphocytes bind via L-selectin to sulfated sialyl-
Lewis
 
x
 
 (sLe
 
x
 
)–containing carbohydrate ligands ex-
pressed on the surface of high endothelial venules 
(HEV). We have examined the expression of sLe
 
x
 
 on 
HEV using a panel of mAbs specific for sLe
 
x
 
 and sLe
 
x
 
-
related structures, and have examined the function of 
different sLe
 
x
 
-bearing structures using an in vitro assay 
of lymphocyte rolling on HEV. We report that three 
sLe
 
x
 
 mAbs, 2F3, 2H5, and CSLEX-1, previously noted 
to bind with high affinity to glycolipid-linked sLe
 
x
 
, vary 
in their ability to stain HEV in different lymphoid tis-
sues and bind differentially to O-linked versus N-linked 
sLe
 
x
 
 on glycoproteins. Treatment of tissue sections with 
neuraminidase abolished staining with all three mAbs 
but slightly increased staining with MECA-79, a mAb 
to a sulfation-dependent HEV-associated carbohydrate 
determinant. Treatment of tissue sections with 
 
O
 
-sia-
loglycoprotease under conditions that removed the vast 
majority of MECA-79 staining, only partially reduced 
staining with the 2F3 and 2H5 mAbs. Using a novel 
rolling assay in which cells bind under flow to HEV of 
frozen tissue sections, we demonstrate that a pool of 
 
O
 
-sialoglycoprotease–resistant molecules is present on 
HEV that is sufficient for attachment and rolling of 
lymphocytes via L-selectin. This interaction is not in-
hibited by the mAb MECA-79. Furthermore, MECA-
79 mAb blocks binding to untreated sections by only 
30%, whereas the sLe
 
x
 
 mAb 2H5 blocks binding by 
 
z
 
60% and a combination of MECA-79 and 2H5 mAb 
blocks binding by 75%. We conclude that a pool of 
 
O
 
-glycoprotease-resistant sLe
 
x
 
-like L-selectin ligands 
exist on human HEV that is distinct from the mucin-
associated moieties recognized by MECA-79 mAb. We 
postulate that these ligands may participate in lympho-
cyte binding to HEV.
 
T
 
hrough 
 
L-selectin, recirculating lymphocytes bind
to and form rolling adhesions on high endothelial
venules (HEV)
 
1
 
 in secondary lymphoid organs. This
brings lymphocytes into intimate contact with the vessel wall
and enables signaling and adhesive interactions through
other molecules responsible for development of firm adhe-
sion and extravasation through the vessel wall (5, 16, 60).
L-selectin–deficient mice have decreased numbers of lym-
phocytes localized to peripheral lymph nodes and are defi-
cient in antigen surveillance in peripheral sites (3, 18, 67).
The L-selectin ligands identified in HEV thus far are
mucin-like molecules bearing fucosylated, sialylated, and
sulfated carbohydrates (6, 7, 13, 36, 52, 53). These include
MAdCAM-1 and CD34. The rat mAb MECA-79 recog-
nizes an antigenic determinant that is closely associated
with the L-selectin ligand; this mAb binds to HEV, inhib-
its lymphocyte binding to HEV, and immunoprecipitates a
group of proteins termed peripheral node addressin (PNAd)
that bind to L-selectin (9, 32, 34, 62). Sialylation of carbo-
hydrate ligands is required for L-selectin binding but not
for MECA-79 mAb recognition, whereas binding of both
L-selectin chimera and MECA-79 requires sulfation (9, 32,
33, 53). Although the location and number of sulfates re-
quired for L-selectin binding is still unknown, sLe
 
x
 
 sul-
 
fated on the 6 position of galactose, i.e., Sia
 
a
 
2
 
®
 
3(SO
 
4
 
-
6)Gal
 
b
 
1
 
®
 
4(Fuc
 
a
 
1
 
®
 
3)GlcNAc, was found to be a major
capping group of the O-linked chains of the L-selectin
ligand GlyCAM-1 and may serve as an important L-selec-
tin recognition structure (31). MECA-79 has been re-
ported to block lymphocyte binding to murine peripheral
lymph node HEV by 95% (62), and it inhibits homing into
lymph nodes in vivo by 
 
z
 
80% (62, 63); however, subse-
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1. 
 
Abbreviations used in this paper
 
: CF, cystic fibrosis; HEV, high endo-
thelial venules; PBMC, peripheral blood mononuclear cells; PNAd, pe-
ripheral node addressin; TBST, Tween-20.
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quent studies have demonstrated incomplete inhibition
of lymphocyte binding to human PNAd (38, 52). More-
over, MECA-79 mAb inhibited binding of human periph-
eral blood mononuclear cells (PBMC) to human periph-
eral lymph node HEV by only 47% (44). PNAd has been
defined as a vascular addressin involved in directing lym-
phocyte homing to peripheral lymph nodes (62). At the
same time, the MECA-79 mAb has been stated to define
this vascular addressin in the mouse (62) and human (9)
and PNAd has been defined as “the isolated complex of
MECA-79–reactive proteins” (32).
Synthetic sLe
 
x
 
 on glycolipid and protein carriers can
serve as an in vitro ligand for L-selectin (2, 54). Immuno-
histochemical studies with mAb to sLe
 
x
 
 or related struc-
tures have demonstrated the presence of sLe
 
x
 
-like moieties
on HEV of human tissues (47, 50, 57), but the relationship
of these moieties to L-selectin ligands has been unclear.
These mAb include: HECA-452, raised against stromal
components of human lymph nodes and that recognizes an
epitope common to both sLe
 
x
 
 and sLe
 
a
 
 (10, 22); CSLEX-1,
raised against the cell surface proteins of adenocarcinoma
tissue; 2F3, raised against a synthetic sLe
 
x
 
 glycolipid, and
2H5, raised against complex sLe
 
x
 
-containing glycolipids
isolated from colon carcinoma tissue (26, 48, 57). Each of
these mAbs to sLe
 
x
 
-like structures has been shown to
block some aspect of selectin-mediated adhesion. E-selec-
tin, expressed on cutaneous vessels in inflamed skin, medi-
ates binding of CLA
 
1
 
 T lymphocytes and this binding is
blocked by the HECA-452 mAb (11, 51). The 2H5 mAb
inhibits L-selectin–dependent adhesion of lymphocytes to
human lymph node HEV, and 2F3 mAb blocks binding of
sLe
 
x
 
-expressing T cell leukemia cells to endothelial E-selec-
tin (48, 57). More recently, both 2F3 and 2H5 have been
reported to inhibit binding of L-selectin–transfected cells
to human lymph node HEV in Stamper-Woodruff assays
(45). Lastly, depletion of CSLEX-1
 
1
 
 T cells was shown to
remove the population capable of binding to E-selectin (21).
In this study we examine the expression of sLe
 
x
 
-like mole-
cules on HEV of human tissues, show differences in the
types of protein backbones that present different sLe
 
x
 
-
related structures, and demonstrate the presence of sLe
 
x
 
-
like molecules distinct from PNAd that can mediate L-selec-
tin binding. Expression of sLe
 
x
 
 by HEV is examined by
immunohistochemical staining of human tissues with a
panel of sLe
 
x
 
-specific mAbs. We report that three sLe
 
x
 
mAbs, 2F3, 2H5, and CSLEX-1, vary in their ability to
stain HEV in various tissues and to recognize sLe
 
x
 
 pre-
sented on different O- and N-linked carbohydrates, al-
though all three mAbs bind with high affinity to sLe
 
x
 
 pre-
sented on glycolipids (26, 48, 57). Furthermore, HEV
staining with the mAbs 2F3 and 2H5 persisted after the
majority of HEV staining with MECA-79 was removed
with 
 
O
 
-sialoglycoprotease treatment, suggesting that addi-
tional, nonmucin structures may present sLe
 
x
 
 on HEV.
Using a rolling assay in which cells attach to HEV of fro-
zen tissue sections under flow conditions, we show that
 
O
 
-sialoglycoprotease–resistant L-selectin ligands exist on
HEV that can mediate attachment and rolling of lympho-
cytes and that this interaction is not inhibited by the mAb
MECA-79. Lastly, we demonstrate that the sLe
 
x
 
 mAb 2H5
inhibits lymphocyte binding to untreated HEV by 
 
z
 
60%,
whereas MECA-79 inhibits binding by only 30%.
 
Materials and Methods
 
Antibodies
 
2F3 (48) and 2H5 (57) mAbs were kindly provided by R. Kannagi (Aichi
Cancer Center, Nagoya, Japan). CSLEX-1 (26) and CSLEA-1 mAbs were
generous gifts of P. Terasaki (University of California Los Angeles, Los
Angeles, CA). FH6 mAb (25) was provided by S. Hakomori (University
of Washington, Seattle, WA). HECA-452 (22) and MECA-79 (62) were
generous gifts of E. Butcher (Stanford University, Stanford, CA). DREG-
56 (35) was a kind gift of T.K. Kishimoto (Boehringer Ingelheim Pharma-
ceuticals, Inc., Ridgefield, CT). P-selectin mAb SZ-51, E-selectin mAb
HAE-1a, and PECAM-1 mAb SG134 were obtained from the Fifth Inter-
national Workshop on Human White Cell Differentiation Antigens
(Kobe, Japan).
 
sLe
 
x
 
-Bearing Glycoproteins
 
The 
 
b
 
-glycyl amine of sLe
 
x
 
 conjugated to BSA was purchased from Ox-
ford Glycosystems (Rosedale, NY). F
 
2b
 
 and glycoprotein respiratory mu-
cin (41) from cystic fibrosis (CF) patients were provided to our laboratory
by G. Lamblin (Unité INSERM, Lille, France). L-selectin/human IgG
 
1
 
chimera (7) was a gift of L. Lasky and S. Watson (both from Genentech
Inc., South San Francisco, CA). sLe
 
x
 
-Decorated L-selectin chimera was
produced by transient co-transfection of COS cells with L-selectin chi-
mera and fucosyl transferase III expression plasmids (24). Culture super-
natants from these cells were collected and L-selectin chimera was puri-
fied using protein A–Sepharose (Sigma Chemical Co., St. Louis, MO).
sLe
 
x
 
-Decorated L-selectin chimera produced in this way bound CSLEX-1
mAb and supported the tethering and rolling of E-selectin–transfected
CHO cells via E-selectin when immobilized on plastic (24). E-selectin–trans-
fected CHO cells were a generous gift of R. Lobb (Biogen Inc., Cam-
bridge, MA) (17).
 
Immunohistochemistry
 
Human tissues from surgical procedures were obtained from Brigham and
Women’s Hospital (Boston, MA) and snap frozen in liquid nitrogen. Thy-
mus was obtained from pediatric patients undergoing cardiac surgery. In-
flamed appendix was obtained from patients with appendicitis and normal
appendix was obtained from a patient with ulcerative colitis undergoing
colectomy; the appendix from this patient was not histologically inflamed.
Mesenteric lymph nodes were also obtained from this patient and were
taken from areas of colon that were not histologically inflamed. “Less re-
active” versus “Highly reactive” tonsil was a qualitative distinction based
on the observation that highly reactive tonsils contained greater numbers
of HEV and had HEV that expressed high levels of P-selectin by immu-
nofluorescence; Less reactive tonsils contained sparse numbers of HEV
that expressed low to undetectable levels of P-selectin. Cryostat sections
(5 
 
m
 
m) were cut and fixed by one of three methods: room temperature ac-
etone for 5 min, 1:1 mixture of acetone and methanol for 2 min at room
temperature, or 2% paraformaldehyde for 10 min at room temperature.
Sections were fixed with acetone unless otherwise noted. Sections were in-
cubated for 45 min with a 40 
 
m
 
g/ml concentration of primary mAb in PBS,
rinsed three times for 5 min each time in PBS, 1% BSA (GIBCO BRL,
Gaithersburg, MD), and incubated for 30 min with a 1:40 dilution of
FITC-conjugated goat anti–rat Ig (Tago Inc., Burlingame, CA) for rat pri-
mary mAbs (HECA-452 and MECA-79) or FITC-conjugated goat anti–
mouse IgG
 
1
 
A
 
1
 
M (Zymed Labs Inc., South San Francisco, CA) for
mouse primary mAbs. Sections were subsequently rinsed three times for 5
min each time in PBS, 1% BSA, and mounted under glass coverslips
(Fisher Scientific Co., Pittsburgh, PA) using mounting media (Fluoro-
mount-G; Southern Biotechnology Associates, Birmingham, AL). Sec-
tions were observed by fluorescence microscopy and photographed imme-
diately after staining.
 
Immunoblot Analysis of sLe
 
x
 
 Antibodies
 
sLe
 
x
 
-Conjugated proteins were spotted onto nitrocellulose and allowed to
dry overnight at room temperature. Blots were blocked for 1 h in 20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20 (TBST) with 1% BSA,
and incubated with 20 
 
m
 
g/ml solution of primary antibodies for 1 h at
room temperature. Blots were then rinsed three times for 7 min each in
TBST and incubated for 30 min in a 1:1,000 dilution of alkaline phos-
phatase-conjugated goat anti–mouse IgG
 
1
 
A
 
1
 
M (Zymed Labs Inc.) in 
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TBST for mouse primary mAbs, or alkaline phosphatase-conjugated rab-
bit anti–rat IgM (Zymed Labs Inc.) in TBST for rat primary mAbs. Blots
were rinsed three times for 7 min each in TBST and developed with West-
ern blue stabilized alkaline phosphatase substrate (Promega Corp., Madi-
son, WI). Reaction was stopped by washing with distilled water.
 
Enzyme Treatment of Tissue Sections
 
Sets of two serial sections of mesenteric lymph node or tonsil (5 
 
m
 
m thick-
ness for immunofluorescence experiments, 9 
 
m
 
m thickness for flow cham-
ber experiments) were prepared and used immediately without fixation.
One of each set of two sections was treated with 100 
 
m
 
l control medium
consisting of HBSS with 1 mM Ca
 
2
 
1
 
 with 1 U/ml DNaseI (from bovine
pancreas; Boehringer Mannheim, Mannheim, Germany) for either 1 h
(neuraminidase control) or 2 h (
 
O
 
-sialoglycoprotease control) at 37
 
8
 
C in a
humidified chamber. The second serial section was treated with 100 
 
m
 
l of
either 0.1 U/ml of neuraminidase (from 
 
Vibrio cholerae
 
; Sigma Chemical
Co.) for 1 h, or 60 
 
m
 
g/ml (0.3 U/ml) 
 
O
 
-sialoglycoprotease (Accurate
Chemical and Scientific Corporation, Westbury, NY) for 2 h at 37
 
8
 
C in a
humidified chamber. Heparitinase I (from 
 
Flavobacterium heparinum
 
;
Sigma Chemical Co.; 600 mU/ml) was added to the solution containing
 
O
 
-sialoglycoprotease and incubated with sections for 2 h at 37
 
8
 
C. En-
zymes were diluted into HBSS, 1 mM Ca
 
2
 
1
 
, containing 1 U/ml DNase.
Sections to be stained with all sLe
 
x
 
 mAbs except CSLEX-1 were rinsed
briefly in PBS, fixed in 2% paraformaldehyde for 10 min at room temper-
ature, and stained as described above. Sections to be stained with CSLEX-1
were rinsed briefly in PBS and fixed in a 1:1 mixture of methanol and ace-
tone for 2 min at room temperature because fixation in paraformaldehyde
eliminated HEV staining with this mAb. The same HEV were identified
in both serial sections so that the reactivity of these HEV with sLe
 
x
 
 mAbs
with and without enzyme treatment could be directly compared. Photographs
of each set of serial HEV were taken using the same exposure time. Sections
to be used in flow experiments were not fixed; sections were rinsed briefly
in PBS and stored at 4
 
8
 
C in PBS for up to 1 h before use.
 
Flow HEV Binding Assay
 
PBMC were isolated as previously described (56). For experiments using
desialylated cells, cells (7.5 
 
3
 
 10
 
6
 
 in 150 
 
m
 
l of HBSS with 2 mM Ca
 
2
 
1
 
, 0.1%
BSA) were treated with 0.1 U/ml of neuraminidase for 40 min at 37
 
8
 
C. For
antibody blocking experiments using DREG-56 mAb, cells (7.5 
 
3
 
 10
 
6
 
 cells
in 150 
 
m
 
l of HBSS with 2 mM Ca
 
2
 
1
 
) were pre-incubated for 40 min on ice
with a final concentration of 50 
 
m
 
g/ml blocking mAb. Freshly cut 9 
 
m
 
m
sections of human tonsil identified as “highly reactive” (see above) were
placed on 70 
 
3
 
 50 mm glass slides (Corning Glass Works, Corning, NY)
pre-coated with 0.1 mg/ml poly-L-lysine (Sigma Chemical Co.), allowed to
dry 1–3 h at room temperature, and then stored at 4
 
8
 
C for up to 2 h until
use. A parallel plate flow chamber was attached directly to the glass slide
such that the tissue section made up the floor of the chamber (19, 38).
PBMC were introduced into the chamber under flow, and the tethering of
cells to HEV at 25
 
8
 
C was observed and recorded using video microscopy.
Flow experiments used the following shear stresses: cells were accumu-
lated at 0.75 dyn/cm
 
2
 
 for 80 s, followed by rinsing with cell-free medium at
1.2, 1.7, 2.1, 3.0, 3.9, 4.8, 6.3, 7.8, 9.3, 10.8, and 12.3 dyn/cm
 
2
 
 for 10 s each.
Binding was evaluated at the end of the 1.7 dyn/cm
 
2
 
 step and the higher
shears were used to remove all adherent lymphocytes from the sections.
In general, an individual section could be used for up to four consecutive
evaluations of cell binding without diminution of lymphocyte attachment
to HEV; after the fourth run, a progressive decrease in lymphocyte bind-
ing was usually observed. Individual sections were therefore used for only
three to four runs. For Figs. 4–6, video images were captured using NIH
Image software version 1.59 and unbound cells were darkened by compar-
ing two consecutive frames and using the minimum value for each pixel.
For antibody-blocking experiments using mAbs MECA-79, 2H5, and 2F3,
cells were first bound to the HEV in the absence of mAb. The mAb (50
 
m
 
g/ml of MECA-79 or culture supernatants of 2H5 or 2F3) was then in-
fused into the flow chamber for 15 min at a rate of 0.02 ml/min. Binding of
cells to the same HEV was then re-evaluated at the end of mAb infusion.
For MECA-79 experiments, mAb at a final concentration of 50 
 
m
 
g/ml was
added to the cell suspension before infusion into the flow chamber and
wash medium was also supplemented with 50 
 
m
 
g/ml MECA-79.
 
Results
 
Staining Patterns of mAbs Recognizing sLe
 
x
 
 and 
Related Stuctures
 
The 2F3, 2H5, and CSLEX-1 sLe
 
x
 
 mAbs stained HEV in
two distinct patterns (Table I). 2F3 and 2H5 mAb brightly
stained the HEV of all lymphoid tissues tested; postcapil-
lary venules in the thymus were not stained. Staining with
these antibodies was intense both in inflamed and in non-
inflamed lymphoid tissues. HEV-staining using CSLEX-1
was much more limited; staining was absent in tonsil, mod-
erate in mesenteric lymph nodes (10–60% of the HEV
were positive), and present at low levels in mucosal lym-
phoid tissue. Staining of appendix HEV with CSLEX-1
mAb correlated with the degree of inflammation as indi-
cated by both patient history and expression by HEV of
P-selectin and E-selectin (Tables I and II). Unlike the
other two mAbs, staining of HEV with CSLEX-1 depended
on the method of fixation. Sections fixed in acetone had the
brightest staining of HEV, sections fixed in methanol and
acetone had less bright staining, and sections fixed in para-
formaldehyde showed no staining of HEV with CSLEX-1.
Both the sLe
 
a
 
 mAb CSLEA-1 and the di-fucosyl sLe
 
x
 
mAb FH6 showed no staining of HEV in any tissue tested.
However, CSLEA-1 did brightly stain the basillar cells of
the tonsillar epithelium and FH6 stained dendritic-like cells
in tonsillar T cell areas, confirming that these mAbs were
active. In agreement with earlier findings that HECA-452
recognizes an epitope common to both sLe
 
x
 
 and sLe
 
a
 
 (10),
the staining pattern of this mAb was found to be a super-
position of that seen with the sLe
 
a
 
 mAb CSLEA-1 and the
sLe
 
x
 
 mAb 2H5 in tonsil, mesenteric lymph node, thymus,
skin, colon, appendix, and breast, with the exception that
 
Table I. High Endothelial Venule (HEV) Staining* in Human Tissues
 
sLe
 
x
 
di-sLe
 
x
 
sLe
 
a
 
HECA-452 MECA-79 P-selectin PECAM-1 2H5 2F3 CSLEX-1 FH6 CSLEA-1
 
Tonsil: less reactive
 
111 111 2 2 2 11 11 1 111
 
Tonsil: highly reactive
 
111 111 2 2 2 111 111 111 111
 
Mesenteric lymph node
 
111 111 11 2 2 111 111 11 111
 
Appendix: normal
 
111 111 2 2 2 11 1 1 111
Appendix: inflamed 111 111 11 2 2 111 11 111 111
Colon lymphoid aggregates 111 111 1 2 2 11 11 1 111
Thymus 2 2 2 2 2 2 2 1 111
*111 Intense staining, 11 moderate staining, 1 low staining, 2 no staining.The Journal of Cell Biology, Volume 140, 1998 724
skin-associated lymphocytes were also stained by HECA-
452 but not by the other mAbs. MECA-79 staining of HEV
was brightest on peripheral HEV, i.e., tonsil, but present
on mucosal HEV, i.e., appendix as well, as has been previ-
ously described (62). Mesenteric lymph nodes were mosaic
for expression of MECA-79 Ag, and contained local clus-
ters of HEV that stained either brightly or weakly with
MECA-79 mAb. P-selectin expression on HEV correlated
with the degree of inflammation as determined by inflam-
matory infiltrate and patient history for appendix, and as
determined by lymphoid hyperplasia for tonsil. PECAM-1
(CD31) staining was universally high on HEV of all tissues
and was used as a positive control.
Immunoblot Analysis of Ligand Specificity of sLex mAbs
All three of the mAbs, 2F3, 2H5, and CSLEX-1 react
strongly with sLex presented by glycolipids (26, 48, 57), yet
CSLEX-1 did not stain HEV at the high levels observed
for the other two mAbs. Using immunoblotting of nitro-
cellulose-immobilized proteins, we examined whether this
differential reactivity with HEV might result from differ-
ences in the structure or presentation of sLex-bearing gly-
cans on glycoproteins bearing O- or N-linked carbohy-
drates.
Fractions of purified mucins from CF patients were used
as a source of sLex bound to mucins. The F2b mucin frac-
tion has been chemically characterized, and contains, among
other compounds, sLex conjugated to mucins via a type II
core structure (41) and the same structure sulfated on the
6 position of GlcNAc, i.e., Siaa2®3Galb1®4(Fuca1®3)
GlcNAc-Core type 2 and Siaa2®3Galb1®4(Fuca1®3),
(SO4-6)GlcNAc-Core type 2. The GP mucin was prepared
by ion-exchange chromatography of the F2b fraction and
contains the less acidic, less sulfated portion of the eluate.
When immobilized on plastic, both mucin fractions sup-
ported rolling of E-selectin–transfected CHO cells and
this rolling was abrogated by treatment of the mucins with
neuraminidase (Ronen Alon, personal communication).
MECA-79 does not bind to the sLex bearing mucins in
these preparations (Fig. 1). sLex sulfated on the 6 position
of galactose, i.e., Siaa2®3(SO4-6)Galb1®4(Fuca1®3)
GlcNAc, was found to be a major capping group of the
O-linked chains of GlyCAM-1, an L-selectin ligand that is
recognized by MECA-79 (32, 34, 36). Undersulfated Gly-
CAM-1 and other L-selectin ligands were not recognized
by MECA-79, suggesting that binding of this mAb to sLex
requires sulfation (32). The absence of sulfation of the
sLex galactose residue in the CF mucins used in this study
may explain their lack of reactivity with MECA-79.
L-selectin chimera decorated with N-linked sLex was pu-
rified from Jurkat cells co-transfected with the L-selectin
chimera and fucosyl-transferase 3. This chimera supported
rolling of E-selectin–transfected CHO cells (24). L-selectin
and the Fc portion of IgG1 contain only N-linked glycosy-
lation sites (8, 15, 58).
Immunoblotting revealed that at identical antibody con-
centrations, mAb CSLEX-1 preferentially bound to L-selec-
tin sLex containing N-linked sLex and BSA-conjugated
sLex but bound weakly to sLex on less acidic mucins (GP)
and did not bind to sLex on the acidic, more highly sul-
fated mucins (F2B) (Fig. 1 a and b). The 2H5 mAb was
found to recognize sLex on less acidic but not on more
acidic mucins or N-linked structures; reactivity with BSA-
sLex was weak but present (Fig. 1 a). In contrast, mAb 2F3
reacted strongly with sLex on all substrates tested (Fig. 1 a
and b), suggesting that it can recognize sLex on glycolipids,
both 6-sulfated and unsulfated sLex-bearing mucins, and
glycoproteins containing N-linked sLex (48). The ability of
this mAb to recognize sLex in a broad variety of contexts
makes it the practical choice for studies that examine tis-
sues or cells for sLex expression.
Treatment of Tissue Sections with Neuraminidase
and O-sialoglycoprotease
To additionally characterize staining by these mAbs, freshly
cut frozen sections of human mesenteric lymph node were
treated with neuraminidase or O-sialoglycoprotease and
then stained with one of the three sLex mAbs. One of the
two serial sections of lymph node was treated with control
medium and the other was treated with enzyme. Particular
HEV were then identified in both sections and their stain-
ing with sLex mAbs was compared in the presence and ab-
sence of enzyme treatment.
Neuraminidase treatment of sections abolished staining
of the three sLex mAbs, 2H5, 2F3, and CSLEX-1, but
slightly increased HEV staining with MECA-79 (Fig. 2).
O-sialoglycoprotease is an enzyme isolated from the bac-
Table II. Staining of Appendix HEV with CSLEX-1 Is Increased 
at Sites of Inflammation*
Specimen
number 1‡ 2‡ 3§ 4§ 5§
CSLEX-1 11 11 2 2
E-selectin 21 12 2 2
P-selectin 111 111 11 11 11
PECAM-1 111 111 111 111 111
*111 Intense staining, 11 moderate staining, 1 low staining, 2 no staining.
‡Histologically inflamed specimen from patient with acute appendicitis.
§Histologically normal specimen from patient with ulcerative colitis.
Figure 1. Binding of sLex antibodies to sLex-containing glycopro-
teins examined by immunoblotting. The indicated amounts of (a)
chemically conjugated BSA-sLex and sLex-presenting respiratory
mucins from CF patients and (b) BSA-sLex and L-selectin chi-
mera decorated with N-linked sLex were blotted on nitrocellulose
and incubated with 20 mg/ml of indicated antibodies.Clark et al. Nonmucin Ligands Support Lymphocyte Rolling on HEV 725
terium  Pasteurella hemolytica that selectively degrades
O-sialomucins (1, 64) and reduces binding of lymphocytes
to immobilized MECA-79 Ag by .90% (52). In keeping
with the ability of this enzyme to cleave PNAd, O-sialogly-
coprotease treatment of tissue sections greatly reduced the
staining of HEV with MECA-79 (Fig. 3). Staining by mAb
directed to the mucin-like region of CD34 (29) was re-
duced by O-sialoglycoprotease to the same extent as for
mAb MECA-79 (data not shown). In contrast, O-sialogly-
coprotease treatment of sections only partially removed
HEV reactivity with 2F3 and 2H5 and left CSLEX-1 reac-
tivity unchanged (Fig. 3). Results are illustrated for mes-
enteric lymph node to include CSLEX-1 mAb, which is
negative on tonsil as described above; however, mAb stain-
ing and sensitivity to enzyme treatment were otherwise
identical on tonsil (data not shown). Staining of HEV in
O-sialoglycoprotease-treated sections with 2F3 and 2H5
was always of greater intensity than with MECA-79. These
findings suggest that 2F3 and 2H5 recognize both a species
of sLex associated with O-sialoglycoprotease–sensitive mu-
cin-like glycoproteins and a species of sLex presented by
O-sialoglycoprotease–resistant glycoproteins or glycolip-
ids. As a control, neuraminidase and O-sialoglycoprotease
treatment of sections had no effect on staining of a non-
sLex control mAb recognizing PECAM-1 (not shown).
Non-PNAd Structures Resistant to 
O-sialoglycoprotease Support Lymphocyte Rolling
The results presented above suggested that a significant
amount of sLex is present on HEV that is not recognized
by MECA-79, but is detected using mAbs, 2F3 and 2H5.
Whether this non-PNAd sLex can support lymphocyte
rolling via L-selectin on HEV is not known. To investigate
this question, we used a novel flow assay to study lympho-
cyte binding to the HEV of human frozen tonsil sections.
Although sections of mesenteric lymph nodes also worked
well in these assays, tonsil was chosen as the preferred roll-
ing substrate because of the presence of large, distinctive
HEV that could be easily identified in serial sections.
Freshly cut sections of human tonsil were attached to glass
slides and placed into a parallel plate flow chamber such
that the tissue section comprised the floor of the chamber.
HEV profiles in the sections could easily be identified by
phase contrast microscopy. Human PBMC were introduced
into the flow chamber at a shear stress of 0.75 dyn/cm2; this
Figure 2. Binding of antibodies to HEV of neuraminidase-
treated sections of human mesenteric lymph node. Freshly cut se-
rial sections were treated for 1 h with (a) control medium or (b)
neuraminidase, fixed, and stained with 40 mg/ml of indicated
mAbs. Identical HEV were observed in each serial section to di-
rectly compare the effects of enzyme treatment. Photographs of
each pair of serial sections were taken and printed using the same
exposure times. Results were identical using tonsil sections ex-
cept that CSLEX-1 did not stain tonsillar HEV.
Figure 3. Binding of sLex antibodies to HEV of O-sialoglycopro-
tease–treated sections of human mesenteric lymph node. Freshly
cut serial sections were treated for 2 h with (a) control medium or
(b) O-sialoglycoprotease, fixed, and stained with 40 mg/ml of in-
dicated sLex mAbs. Identical HEV were compared in each serial
section and photographs of each set of serial sections were taken
using identical exposure times. Results using tonsil sections were
identical except that CSLEX-1 did not stain tonsillar HEV.The Journal of Cell Biology, Volume 140, 1998 726
shear stress is permissive for efficient L-selectin tethering
(23). Cells tethered to HEV under flow, and either became
firmly adherent to the HEV or rolled along the wall of the
HEV in the direction of flow. Once rolling cells reached
the end of an HEV profile, they detached from the section
and occasionally re-attached to an HEV further down-
stream. Most striking was the ability of cells to actually roll
down the length of the HEV endothelial wall; this was par-
ticularly apparent for longitudinally cut HEV that were
oriented in the direction of flow, as shown in Figs. 4 and 5.
A shear strength of 0.75 dyn/cm2 was routinely used for
cell attachment; at this shear strength, virtually all of the
cell attachment to the section was to HEV profiles. At
lower shear strengths in the range of 0.2–0.5 dyn/cm2, some
tethering of lymphocytes was also seen to extracellular
matrix associated with reticular fibers. Prior studies have
shown that this binding likely represents interaction of
lymphocytes with hyaluronan or tenascin (19, 20).
Binding of PBMC to HEV under flow (Fig. 4) was only
partially blocked by L-selectin mAb DREG-56 (Fig. 4 c),
but completely blocked by EDTA (Fig. 4 d). A subset of
lymphocytes express ligands for P-selectin and E-selectin
(54, 60); staining of tonsil sections with mAbs revealed
that most HEV expressed P-selectin (Table I). All selectin
ligands require sialylation for activity (54). We, therefore,
treated mononuclear cells with neuraminidase to eliminate
any binding contribution by P-selectin or E-selectin (Fig.
4 g) and found that binding was then almost completely
blocked by L-selectin mAb DREG-56 (Fig. 4 h). To exam-
ine the effects of neuraminidase and O-sialoglycoprotease
on cell binding, one of two serial sections of human tonsil
were treated with control medium and the other was treated
Figure 4. Binding of PBMC under flow conditions to HEV of
frozen sections of human tonsil. To clearly delineate HEV
boundaries, phase contrast images taken before binding of lym-
phocytes and focused in the plane of the section are shown in (a
and e). Other panels used a focal plane in the plane of the binding
lymphocytes and the venule structure is less clearly seen. Binding
of (b) untreated PBMC, (c) DREG-56–treated PBMC, and (d)
PBMC in the presence of 5 mM EDTA to an HEV. Binding to
(e), a second HEV, was evaluated using (f) untreated PBMC, (g)
neuraminidase-treated PBMC, and (h) neuraminidase-treated
PBMC pre-incubated with DREG-56. Cells were accumulated at
0.75 dyn/cm2 for 80 s, followed by rinsing with cell-free medium
at 1.2, 1.7, and 2.1 dyn/cm2 for 10 s each. Under increasing shear,
cells were observed to roll along the walls of HEV oriented in the
direction of flow. Video images were captured at the end of the
1.7 dyn/cm2 step using NIH Image software version 1.59; un-
bound cells were darkened by comparing two consecutive frames
and using the minimum value for each pixel. The direction of
flow was from the bottom of the figure to the top.
Figure 5. Binding of neuraminidase-treated PBMC under flow
conditions to HEV of human tonsil sections treated with
neuraminidase or O-sialoglycoprotease. To clearly delineate
HEV boundaries, phase contrast images focused in the plane of
the section taken before lymphocyte binding are shown in (a, c, e,
and g). Binding of cells to HEV of serial sections treated for 1 h
with (a and b) control medium or (c and d) neuraminidase or for
2 h with (e and f) control medium or (g and h) O-sialoglycopro-
tease. Binding to identical HEV in the control and enzyme-
treated serial sections were examined in order to directly com-
pare the effects of enzyme treatment. Flow parameters were
identical to those used in Fig. 4. The direction of flow was from
the bottom of the figure to the top.Clark et al. Nonmucin Ligands Support Lymphocyte Rolling on HEV 727
with enzyme under the same conditions as used in Figs. 2
and 3. Binding of cells to profiles of the same HEV was
then compared in the enzyme-treated and control-treated
serial sections (Fig. 5). Binding of neuraminidase-treated
cells (Fig. 5 b) was virtually eliminated by neuraminidase
treatment of the section (Fig. 5 d). However, under condi-
tions that almost completely removed MECA-79 reactivity
(Fig. 3), treatment of sections with O-sialoglycoprotease only
partially inhibited the binding of neuraminidase-treated
cells to HEV (compare Fig. 5, f and h). In the experiment
shown, 33 cells bound to the HEV treated with control
medium and 21 cells bound to the HEV treated with
O-sialoglycoprotease. In experiments with 10 different pairs
of serial sections, binding to O-sialoglycoprotease–treated
sections was 71 6 11% of binding to control sections (Ta-
ble III). Inclusion of DREG-56 mAb blocked lymphocyte
binding to HEV after O-sialoglycoprotease treatment of
sections, confirming that this binding remained L-selectin
dependent (data not shown). Prior studies have demon-
strated the presence of glycoprotein L-selectin ligands on
arterial endothelium that are partially destroyed by hep-
arin lyases (28); we, therefore, incubated sections with a
combination of heparitinase I and O-sialoglycoprotease,
but found no additional inhibition of binding from hep-
aritinase treatment (see Fig. 7).
Because treatment of sections with O-sialoglycopro-
tease did not completely remove HEV staining with the
MECA-79 mAb, we could not rule out the possibility that
the remaining PNAd was contributing to lymphocyte bind-
ing. MECA-79 mAb was therefore used to block binding
of neuraminidase-treated lymphocytes to both untreated
and O-sialoglycoprotease–treated sections. When HEV were
tested for lymphocyte binding both before and after infu-
sion of blocking mAb, MECA-79 mAb reduced lympho-
cyte binding to HEV of untreated sections to 60–80% of
control levels (Fig. 6 b). In the experiment shown, 62 cells
bound to HEV before MECA-79 treatment (Fig. 6 a) and
44 cells bound after mAb treatment (Fig. 6 b). Infusion of
a control CD31 IgM mAb in duplicate experiments had no
effect on lymphocyte binding to HEV (data not shown). In
sections treated with O-sialoglycoprotease, MECA-79 mAb
did not affect binding of lymphocytes to HEV (Fig. 6 c and
d). In the experiment shown, 44 cells bound to the HEV
before mAb treatment (Fig. 6 c) and 46 cells bound after
treatment (Fig. 6 d). Six experiments confirmed that al-
though MECA-79 mAb did decrease binding of cells to
untreated HEV, the mAb had no effect on lymphocyte
binding to HEV treated with O-sialoglycoprotease (Table
IV). Similar results were obtained when cells were accu-
mulated at a lower shear stress of 0.38 dyn/cm2 (data not
shown). With respect to the concentration of MECA-79
used for blocking, these experiments used MECA-79 at 50
mg/ml; additional experiments using MECA-79 mAb at a
concentration of 100 mg/ml produced similar results (data not
shown). In vitro flow studies have demonstrated .85% in-
hibition of lymphocyte binding to purified human PNAd
using MECA-79 mAb at 20 mg/ml (52). The results of
these experiments suggest that PNAd mediates only part
of lymphocyte binding to untreated HEV and does not
contribute to lymphocyte binding to HEV in O-sialoglyco-
protease–treated sections.
sLex mAb 2H5 Inhibits Binding to Human HEV under 
Shear Flow
To determine if MECA-79-resistant lymphocyte binding
in the flow assay to HEV was indeed mediated by sLex-
like molecules, tonsil sections were treated with the sLex
mAb 2H5. Whereas MECA-79 mAb reduced lymphocyte
binding to HEV by 29 6 6%, mAb 2H5 reduced binding
by 57 6 11%. Furthermore, a combination of the two
mAbs reduced binding by 74 6 6%. These results demon-
Table III. Effect of O-sialoglycoprotease Treatment on Lymphocyte Binding to HEV*
Section Treatment
Number of lymphocytes bound to HEV
Percent of control
binding , 6 SD Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6 Exp. 7 Exp. 8 Exp. 9 Exp. 10
Serial section 1 Control medium 33 40 23 45 47 36 37 28 33 31 100
Serial section 2 O-sialo- 21 33 17 26 37 29 24 19 28 17 71 6 11
glycoprotease
*The same HEV in serial sections was identified for comparison of cell binding.
Figure 6. Effect of MECA-79
mAb on binding of neuramini-
dase-treated PBMC under
flow conditions to HEV of
(a and b) untreated and (c
and  d)  O-sialoglycoprotease–
treated tonsil sections. Bind-
ing to an individual HEV was
assessed before (a and c) and
(b and d) after incubation of
sections with MECA-79 mAb.
Flow parameters were identi-
cal to those used in Fig. 4.
The direction of flow was
from the bottom of the figure
to the top.The Journal of Cell Biology, Volume 140, 1998 728
strate that sLex-like molecules, distinct from PNAd, sup-
port L-selectin–mediated attachment of lymphocytes to
human HEV.
Discussion
The adhesion of lymphocytes to the surface of HEV via
L-selectin is a crucial step in lymphocyte recirculation. Al-
though the only known ligands of L-selectin on HEV are
mucin-like molecules, sLex-containing glycolipids and pro-
teins have been shown to bind L-selectin in vitro (2, 12,
54). Previous immunohistochemical studies of the expres-
sion of sLex by HEV have produced conflicting reports,
only some of which can be explained on the basis that dif-
ferent sLex mAbs were used for staining. For example, in
studies using the mAb CSLEX-1, different groups found
expression of sLex by both peripheral lymph nodes and
mucosal lymphoid tissue (47), by peripheral lymph nodes
but not mucosal lymphoid tissue (50), and by neither pe-
ripheral lymph nodes nor mucosal lymphoid tissue, except
for a faint staining of peripheral lymph nodes at high anti-
body concentrations (57). Similar disagreement exists about
the expression of the structurally related selectin ligand
sLea (12), which has been reported to be expressed by
HEV (30, 50) and not expressed by HEV (57).
In this study, we stained a common set of tissues with a
panel of mAbs against sLex and related structures. We
found that three sLex mAbs, CSLEX-1, 2F3, and 2H5,
stained the HEV of lymphoid organs in two distinct pat-
terns. 2F3 and 2H5 stained the HEV of all lymphoid tis-
sues tested at a constitutively high level that was not in-
creased by the presence of inflammation. In contrast,
CSLEX-1 weakly stained the HEV of mucosal lymphoid
tissues and a subset of HEV in mesenteric lymph nodes,
and this staining was enhanced when these organs were in-
flamed. Staining of HEV with mAb 2H5 has been previ-
ously reported (57). Our finding that 2F3 mAb stains pe-
ripheral lymph node HEV is in agreement with a recent
report (45). However, this study failed to detect CSLEX-1
staining of HEV, most likely because tissue sections were
fixed with paraformaldehyde before staining. Indeed, the
staining pattern we observed with CSLEX-1 mAb was
found to depend upon the method of tissue fixation. HEV
staining with CSLEX-1 has also been shown to depend on
the concentration of mAb used in staining; in one study, 1
mg/ml mAb produced no staining of HEV in the lymph
node but 10 mg/ml mAb did produce positive lymph node
staining (57). Variation among reports (47, 50, 57) on abil-
ities of CSLEX-1 mAb to stain HEV are most likely re-
lated to both the concentration of mAb and the different
methods of fixation used in these studies. mAbs recogniz-
ing sLea (CSLEA-1) and di-fucosyl sLex (FH6) did not
stain the HEV of any tissue tested, in agreement with stud-
ies by Sawada et al. (57). The mAb HECA-452 stained
HEV and non-HEV structures in a pattern that was the
sum of the sLex staining pattern with 2H5 and the sLea
staining pattern with CSLEA-1, with the exception that
lymphocytes in the skin were also positive (51). MECA-79
mAb stained the HEV of both peripheral and mucosal lym-
phoid tissues, although staining of peripheral lymphoid HEV
was brighter, in agreement with earlier reports (42, 63).
Immunoblotting of immobilized mucins bearing sLex,
glycoprotein bearing N-linked sLex, and BSA chemically
conjugated to sLex showed that mAb CSLEX-1 preferen-
tially bound N-linked and BSA-sLex, reacted weakly with
a population of sLex-bearing mucins, and did not react
with acidic mucin fractions known to contain sLex sulfated
on the 6 position of GlcNAc. These findings are consistent
with recent studies showing that CSLEX-1 recognizes sLex
but not 6-sulfated sLex (45). In contrast, 2H5 mAb was
found to recognize sLex on less acidic mucins but not on
more acidic mucins or on N-linked structures, and mAb
2F3 recognized sLex on all substrates tested. The mAb
2F3, therefore, has the broadest sLex specificity, recogniz-
ing sLex when conjugated to glycolipids (57), mucins con-
taining sLex and 6-sulfo-sLex, and sLex N-linked to glyco-
proteins. In support of our findings that the 2F3 mAb
Table IV. Effect of MECA-79 mAb on Lymphocyte Binding to HEV*
Section treatment Ab treatment
Lymphocyte binding to HEV
Percent of
binding 6 SD Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6
Control medium 2MECA-79 62 56 40 47 60 48 100
Control medium 1MECA-79 44 34 31 34 45 32 71 6 6.1
O-sialoglycoprotease 2MECA-79 44 47 38 66 29 41 100
O-sialoglycoprotease 1MECA-79 46 45 39 63 30 43 101 6 4.3
*Binding to a particular HEV was counted before and after antibody addition.
Figure 7. Effect of treatment of tonsil sections with sLex mAbs,
O-sialoglycoprotease (OG), and heparitinase (Heparit.) on bind-
ing of neuraminidase-treated PBMC. Flow parameters for all ex-
periments were identical to those used in Fig. 4. Binding to an in-
dividual HEV was assessed before and after incubation of
sections with sLex mAb. Enzyme experiments were conducted as
described in Fig. 5. Mean values of at least six experiments are
shown with the standard deviation indicated by bars.Clark et al. Nonmucin Ligands Support Lymphocyte Rolling on HEV 729
binds to forms of sLex not recognized by CSLEX-1, skin-
infiltrating adult T cell leukemia cells have been shown to
express high levels of sLex as measured by reactivity with
the 2F3 mAb, but these cells exhibited no reactivity with
the CSLEX-1 mAb (27).
The 2H5 and CSLEX-1 mAbs are known to require
sialic acid for binding (26, 57). In agreement with these re-
ports, treatment of tissue sections with neuraminidase com-
pletely eliminated binding of the 2F3, 2H5, and CSLEX-1
mAbs to HEV. Binding of MECA-79 to HEV was slightly
enhanced by neuraminidase treatment, consistent with in
vitro studies showing that binding of MECA-79 to its epi-
tope is increased by neuraminidase treatment, although
desialylation destroys L-selectin ligand activity (9, 32, 55).
O-sialoglycoprotease recognizes O-linked carbohydrate
groups and cleaves the polypeptide chain nearby (43). It
cleaves mucin-like surface molecules such as CD43 and
glycophorin A, and selectively cleaves mucin-like regions
of CD34, CD44, and CD45. Afterwards, the membrane-
proximal nonmucin–like regions of CD34 and CD45 re-
main on the cell surface, and the membrane-distal nonmu-
cin–like region of CD44 is released (1, 29, 64). Nonmucin
proteins that are O-glycosylated, such as fetuin, are not
cleaved (43). The NH2-terminal but not COOH-terminal
threonine and proline-rich repeats of the P-selectin glyco-
protein ligand are cleaved by O-sialoglycoprotease (40,
46). It appears safe to conclude that all glycoproteins
cleaved by O-sialoglycoprotease contain mucin-like regions;
however, by no means will all proteins containing O-linked
carbohydrate be cleaved. O-sialoglycoprotease treatment of
immobilized PNAd that was purified with MECA-79 mAb
from tonsil reduces its ability to support L-selectin–depen-
dent lymphocyte binding by .90% (52). Here, treatment
of sections with O-sialoglycoprotease almost completely
eliminated staining with MECA-79 mAb, and completely
eliminated the MECA-79 mAb-inhibitable component of
lymphocyte binding. Thus, almost all MECA-79 antigen is
associated with mucin-like proteins. By contrast, treat-
ment of sections with O-sialoglycoprotease had no effect
on CSLEX-1 staining, and only partially decreased stain-
ing with 2H5 and 2F3 mAb. The results with CSLEX-1 are
in agreement with immunoblotting results that show that
this mAb recognizes sLex-bearing mucins very poorly, and
preferentially binds to sLex presented on different struc-
tures such as N-linked glycoproteins. The partial decrease
in HEV staining with the 2F3 and 2H5 mAbs with O-sia-
loglycoprotease treatment indicated that the high levels of
HEV staining we observed with these mAbs represent two
pools of sLex, one associated with mucin-like glycopro-
teins, and another associated with glycolipids or O-sia-
loglycoprotease–resistant glycoproteins. The recognition
of sLex associated with mucin-like glycoproteins by 2F3
and 2H5 is consistent with our immunoblotting results that
show recognition of sLex-bearing CF mucins by these two
mAbs. Earlier studies have shown that the 2F3 and 2H5
mAbs recognize glycoprotein-linked sLex, although not nec-
essarily presented by mucins. The 2F3 mAb recognized
both sLex presented on glycolipids and a distinct set of
O-linked oligosaccharides from glycoproteins derived from
human cancer tissues, and 2H5 immunoprecipitated a group
of glycoproteins from preparations of human lymph node
in addition to reaction with sLex on glycolipids (48, 57).
The finding that 2F3 and 2H5 mAbs recognize a pool of
HEV sLex that is resistant to O-sialoglycoprotease, and
thus distinct from the mucin-associated carbohydrate struc-
tures recognized by MECA-79 mAb, raised the possibility
that other molecules bearing sLex on HEV may act as
L-selectin ligands. The 2H5 mAb recognizes a functional
L-selectin ligand on HEV as shown by its ability to par-
tially block the adhesion of lymphocytes to sections of hu-
man lymph node (57). This functional effect could result
either from blocking by 2H5 of the same mucin-sLex sites
as MECA-79, or from blocking of additional L-selectin
ligand sites recognized by 2H5, but not by MECA-79. The
latter possibility is supported by the finding that 2H5 im-
munoprecipitates a set of glycoproteins bearing O-linked
sLex from lymph nodes that is distinct from the set of pro-
teins immunoprecipitated from the same tissue using
MECA-79 (9, 57). 2F3 has also recently been reported to
block adhesion of L-selectin–transfected cells to human
HEV, although the dependence of this effect on L-selectin
was not clearly established (45). 
To examine the possibility that 2F3 and 2H5 staining of
HEV may reflect the presence of ligands for L-selectin that
are related to sLex but distinct from PNAd, we used a
novel rolling assay in which peripheral blood lymphocytes
attached under flow to the HEV of sections prepared from
frozen human tonsil. In the Stamper-Woodruff assay (61),
lymphocytes are overlaid onto frozen sections of human
lymph nodes, and incubated with gentle agitation. Lym-
phocyte binding to morphologically distinct HEV is then
examined by light microscopy. The flow assay used in this
study resembles the Stamper-Woodruff assay in that it
uses frozen sections, but has the additional advantages of
selectively visualizing interactions that are capable of me-
diating tethering and rolling under flow, and allowing use
of defined shear stresses. The initial tethering and rolling
steps of lymphocyte adhesion to HEV can be directly ob-
served, and are therefore separable from steps involving
firm attachment. Furthermore, our assay is suitable for use
on human specimens and allows in vitro manipulations. In-
travital microscopy offers many advantages for studies of
lymphocyte homing (4, 39, 65), but is limited to animal
models and to the degree of experimental manipulation.
In contrast to intravital microscopy, in both the standard
and flow version of the Stamper-Woodruff assay, it is pos-
sible that the cells attaching to HEV are binding to ligands
on the cell surface of the HEV or to molecules in intracel-
lular compartments. P-selectin, usually confined to storage
vesicles in unstimulated endothelium, may mediate some
binding of lymphocytes in this assay; E-selectin, often present
on the surface of stimulated HEV, could also contribute to
binding. However, binding to both P- and E-selectin was
eliminated in our studies by pretreatment of the lympho-
cytes with sialidase. Furthermore, the 2F3 and 2H5 mAbs
to sLex clearly stained the surface of HEV, with the greatest
concentration of staining present on the lumenal surface of
the HEV. Despite possible limitations, the Stamper-Wood-
ruff assay has been remarkably robust, and has enabled
identification of all known receptors and ligands involved
in homing to date, including L-selectin, PNAd, the integrin
a4b7, and MAdCAM-1 (16, 60).
Using the flow assay described here, we found that bind-
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pletely blocked by EDTA and by the L-selectin mAb
DREG-56, confirming that L-selectin alone contributed to
binding under these conditions. Neuraminidase treatment
of sections completely blocked lymphocyte binding to
HEV, in agreement with studies done using Stamper-
Woodruff assays in the mouse (55). In contrast, treatment
of sections with O-sialoglycoprotease under conditions
that virtually eliminated MECA-79 staining, only partially
inhibited cell attachment to HEV. Cell binding to O-sia-
loglycoprotease–treated sections averaged 71% of binding
to sections treated with control medium. Incubation of
O-sialoglycoprotease–treated sections with MECA-79 mAb
did not further diminish lymphocyte binding to HEV, sug-
gesting that the residual MECA-79 antigen present after
enzyme treatment did not significantly contribute to lym-
phocyte binding. This functional pool of O-sialoglyco-
protease–resistant L-selectin ligands may include the sLex
detected by mAb 2F3 and 2H5 on O-sialoglycoprotease–
treated sections.
Studies on untreated HEV sections also supported a dis-
tinction between the L-selectin ligands associated with
2H5 epitopes and MECA-79 epitopes, and showed that
the former are more functionally important. Approxi-
mately one-half of lymphocyte binding through L-selectin
was blocked by 2H5 mAb, one-quarter was blocked by
MECA-79 mAb, and blocking by these mAbs was addi-
tive. These results clearly demonstrate the presence of sLex-
like L-selectin ligands on HEV that are capable of binding
lymphocytes and that are distinct from the moieties recog-
nized by MECA-79. In agreement with our hypothesis that
2H5-reactive material can support lymphocyte binding,
this mAb has recently been shown to block binding of
L-selectin–transfected cells to HEV of human lymph node
sections in classical Stamper-Woodruff assays (45).
We conclude from these studies that L-selectin ligands
distinct from those recognized by MECA-79 exist on hu-
man HEV, and that these ligands are capable of support-
ing rolling lymphocyte adhesion in flow. Furthermore, struc-
tural moieties that are O-glycoprotease resistant, and that
bear sLex and L-selectin ligand activity but lack MECA-79
antigen, are present on HEV. Our studies dissociate for
the first time on HEV ligands for L-selectin that are O-gly-
coprotease resistant from ligands for L-selectin that are as-
sociated with mucin-like counter receptors and MECA-79
antigen. Our studies have been confined to human tissue.
Inhibition by MECA-79 mAb of the Woodruff-Stamper
assay in the mouse is greater than in the human yet still in-
complete, as is inhibition of homing to peripheral lymph
nodes in the mouse (14, 38, 44, 62, 63). Therefore, two
classes of L-selectin ligands may also be present in mouse,
although that associated with MECA-79 antigen appears
to be more predominant.
Historically, two independent approaches have been
used to identify ligands important in homing on peripheral
lymph node HEV. The first used MECA-79 mAb (62), and
the second used L-selectin itself as a probe for ligand ac-
tivity (66). The mAb MECA-79 has been an extremely
useful tool in characterizing this ligand both in the mouse
and human. In the course of work with MECA-79 mAb,
it was described as “an anti-peripheral lymph node ad-
dressin mAb” and peripheral node addressin was defined
as “the isolated complex of MECA-79-reactive proteins,”
even in studies that directly compared materials affinity
isolated with MECA-79 mAb and L-selectin (32). The cur-
rent study demonstrates that MECA-79 antigen and mate-
rial that functions in L-selectin-dependent rolling on HEV
sections are overlapping but distinct moieties. This com-
plexity in L-selectin ligands is in agreement with the com-
plexity of O- and N-glycans in general, and with the pres-
ence of an L-selectin ligand on leukocytes, despite absence
of reactivity of MECA-79 mAb with leukocytes (5, 24, 49,
59). Our work suggests that it would be best to return to
the original, functional definition of addressins (63), and to
associate the term peripheral node addressin with L-selectin
ligand activity rather than MECA-79 antigen.
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